Meisner Derek M 4

What Happened
Derek M. Meisner, Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals (ABOS), disposed of a total of 8,934 shares in open-market sales across three dates (Jan 21–23, 2026) for aggregate proceeds of about $16,720. The reported transactions: 2,247 shares at a weighted average $1.81 ($4,063), 1,054 shares at $1.84 ($1,939), and 5,633 shares at $1.90 ($10,718). These were sales (S) — routine disposals rather than purchases.

Key Details

• Transaction dates: 2026-01-21, 2026-01-22, 2026-01-23. Report filed 2026-01-23 (appears timely).
• Reported prices: weighted averages $1.81, $1.84, $1.90; underlying trade prices ranged from $1.76–$1.87 and $1.88–$1.94 per footnotes.
• Total shares sold: 8,934; total proceeds ≈ $16,720.
• Shares owned after the transactions: not stated in the provided filing data.
• Notable footnotes: some shares were sold as automatic "sell-to-cover" to satisfy tax withholding related to RSU vesting under a Rule 10b5‑1 plan; other shares were sold pursuant to a separate Rule 10b5‑1 trading plan. Weighted-average prices reflect multiple trades within the reported ranges.

Context
Sales executed under 10b5‑1 plans and sell-to-cover transactions are common mechanisms for insiders to meet tax obligations or follow pre-set trading plans; such sales are routine and do not necessarily indicate a change in the insider's view of the company. Retail investors should consider these filings as one data point alongside company fundamentals and broader insider activity.